- GuruFocus.com•4 hours ago
Stocks mixed with gains led by Johnson & Johnson and Pfizer
- American City Business Journals•5 hours ago
United Therapeutics Corp. (UTHR) blames increasing competition in the pulmonary arterial hypertension space for its lower-than-expected revenue last year, CEO Martine Rothblatt told analysts Wednesday. During the Silver Spring-based company's fourth-quarter earnings call, Rothblatt said there has been weaker growth for some of its drugs — Orenitram, Tyvaso and Remodulin. Patients are sticking with alternative therapies, such as a combination of Adcirca with Letairis, longer than expected before switching to its products, she said.
- MarketWatch•6 hours ago
U.S. stocks retreat modestly on Thursday, pulling back from intraday records as technology stocks struggle amid persistent concerns about lofty valuations and the prospects for fiscal stimulus a day after ...
JNJ : Summary for Johnson & Johnson Common Stock - Yahoo Finance
Johnson & Johnson (JNJ)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||119.48 - 121.90|
|52 Week Range||104.77 - 126.07|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.52|
|Dividend & Yield||3.20 (2.67%)|
|1y Target Est||N/A|